Breakthrough technology to preserve live pancreatic tissue for at least 10 days provides a window into the organ’s ability to regenerate
Credit: Diabetes Research Institute Foundation
MIAMI, FL – June 29, 2020 – Scientists from the Diabetes Research Institute (DRI) at the University of Miami Miller School of Medicine have developed a method allowing for the long-term culture of “pancreatic slices” to study the regeneration of the human pancreas in real time. The results, published this week in the journal of Nature Communications, demonstrate for the first time that extended cultures of near-intact human pancreatic tissue retain the ability of the live organ to replenish insulin-producing beta cells. The use of this system as a model to study pancreatic regeneration could have important therapeutic implications for the treatment of diabetes.
Pancreatic slices are very thin live sections of the organ that preserve the cellular architecture and cell-to-cell interactions of the native organ. The generation of slices from human donors was first accomplished at the DRI in the context of an initiative sponsored by the Network for Pancreatic Donors with Diabetes (nPOD). However, slices are fragile and usually disintegrate in culture very quickly due to self-digestion and lack of sufficient oxygenation. Such rapid deterioration was incompatible with the study of the regeneration of insulin-producing beta cells, which are destroyed by autoimmunity in type 1 diabetes. However, DRI scientists circumvented this problem by placing the slices on a culture device that enhances the oxygenation of the tissue. This led to the extended survival and biological function of the slices for many days.
“The ability to keep human pancreatic slices alive for nearly two weeks is a technical breakthrough that allows us to witness the regeneration of beta cells in a human model that strongly resembles the real pancreas,” said Dr. Juan Domínguez-Bendala, Director of Stem Cell Development for Translational Research and Research Associate Professor of Surgery at the Diabetes Research Institute, University of Miami Miller School of Medicine, and principal investigator of this work. “We now have a window into the native human organ that simply wasn’t possible prior to this study.”
The DRI’s research on regeneration focused on a population of stem-like “progenitor” cells that had been previously characterized by this team in the human pancreas – a pool of cells that remains intact even in patients with long-standing type 1 diabetes. These cells were shown to respond to a natural growth factor, BMP-7, by proliferating and subsequently giving rise to insulin-producing beta cells.
“Extending the life of these slices in culture was key to observe beta cell regeneration in real time following the addition of BMP-7, even in slices obtained from diabetic donors. This gives us hope that we may be able to apply this approach to living patients one day,” said Ricardo Pastori, Ph.D., Research Professor of Medicine, Immunology, and Microbiology and the Director of the Molecular Biology Laboratory at the Diabetes Research Institute, University of Miami Miller School of Medicine and co-principal investigator of this study.
The findings and system utilized here will continue to impact future studies of the human pancreas. Considering that preclinical work in animals often translates poorly to humans, this in vitro model of the human pancreas could be used to screen for additional regenerative agents with an unparalleled degree of accuracy when it comes to predicting responses in patients. This could lead to a faster and more certain path to clinical trials for type 1 and type 2 diabetes.
About the Diabetes Research Institute
The Diabetes Research Institute at the University of Miami Miller School of Medicine leads the world in cure-focused research. As one of the largest and most comprehensive research centers dedicated to curing diabetes, the DRI is aggressively working to develop a biological cure by restoring natural insulin production and normalizing blood sugar levels without imposing other risks. Researchers have already shown that transplanted islet cells allow patients to live without the need for insulin therapy. Some study participants have maintained insulin independence for more than 10 years. The DRI is now building upon these promising outcomes through its BioHub strategy, a multidisciplinary, three-pronged approach for addressing the major challenges that stand in the way of a cure: eliminate the need for anti-rejection drugs, reset the immune system to block autoimmunity, and develop an unlimited supply of insulin-producing cells. For more information, please visit DiabetesResearch.org or call 800-321-3437.
Related Journal Article